Millipore Sigma Vibrant Logo

480415 NF023 - Calbiochem

A suramin analog that acts as a selective and direct G-protein antagonist for α-subunits of the Go/Gi group (EC₅₀ ~ 300 nM).

NF023 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: 8,8ʹ-[Carbonylbis(imino-3,1-phenylene)]bis-(1,3,5-naphthalenetrisulfonic Acid), 6Na, P2X Antagonist I, Purinergic Receptor P2X Antagonist I

Primary Target: α-subunits of the Go/Gi group of G-protein
View Products on Sigmaaldrich.com
480415
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

Empirical Formula
C₃₅H₂₀N₄O₂₁S₆ · 6Na

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
480415-10MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 10 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA suramin analog that acts as a selective and direct G-protein antagonist for α-subunits of the Go/Gi group (EC50 ~ 300 nM). Suppresses GTPγS binding to recombinant G-protein α-subunits. Acts by inhibiting the formation of the agonist-specific ternary complex (agonist/receptor/G-protein). NF023 does not interfere with the interaction between α-subunits and βγ-dimer but competes with the effector binding site. Also a P2X receptor antagonist (IC50 = 240 nM for P2X1; 8.5 µM for P2X3 receptor in rat muscle). Causes a concentration dependent inhibition of excitatory junction potentials (IC50 = 4.8 pM).
      Catalogue Number480415
      Brand Family Calbiochem®
      Synonyms8,8ʹ-[Carbonylbis(imino-3,1-phenylene)]bis-(1,3,5-naphthalenetrisulfonic Acid), 6Na, P2X Antagonist I, Purinergic Receptor P2X Antagonist I
      References
      ReferencesSnedden, P., et al. 2000. Br. J. Pharmacol. 129, 1089.
      Soto, F., et al. 1999. Neuropharmacology 38, 141.
      Beindle, W., et al. 1996. Mol. Pharmacol. 50, 415.
      Freissmuth, M., et al. 1996. Mol. Pharmacol. 49, 602.
      Product Information
      ATP CompetitiveN
      FormWhite to off-white solid
      Hill FormulaC₃₅H₂₀N₄O₂₁S₆ · 6Na
      Chemical formulaC₃₅H₂₀N₄O₂₁S₆ · 6Na
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetα-subunits of the Go/Gi group of G-protein
      Primary Target IC<sub>50</sub>240 nM for P2X1; 8.5 µM for P2X3 receptor in rat muscle; 4.8 pM in the inhibition of excitatory junction potentials; EC50 ~ 300 nM as G-protein antagonist for α-subunits of the Go/Gi group
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      480415-10MG 04055977201345

      Documentation

      NF023 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      NF023 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      480415

      Références bibliographiques

      Aperçu de la référence bibliographique
      Snedden, P., et al. 2000. Br. J. Pharmacol. 129, 1089.
      Soto, F., et al. 1999. Neuropharmacology 38, 141.
      Beindle, W., et al. 1996. Mol. Pharmacol. 50, 415.
      Freissmuth, M., et al. 1996. Mol. Pharmacol. 49, 602.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-June-2018 JSW
      Synonyms8,8ʹ-[Carbonylbis(imino-3,1-phenylene)]bis-(1,3,5-naphthalenetrisulfonic Acid), 6Na, P2X Antagonist I, Purinergic Receptor P2X Antagonist I
      DescriptionA suramin analog that acts as a selective G-protein antagonist for α-subunits of the Go/Gi group (EC50 ~300 nM). Suppresses GTPγS binding to recombinant G-protein α-subunits. Acts by inhibiting the formation of the agonist-specific ternary complex (agonist/receptor/G-protein). NF023 does not interfere with the interaction between α-subunits βγ-dimer but competes with the effector binding site. Also a P2X receptor antagonist (IC50=0.24 µM for P2X1; 8.5 µM for P2X3 receptor in rat muscle).
      FormWhite to off-white solid
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₃₅H₂₀N₄O₂₁S₆ · 6Na
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityH₂O
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions.
      Toxicity Standard Handling
      ReferencesSnedden, P., et al. 2000. Br. J. Pharmacol. 129, 1089.
      Soto, F., et al. 1999. Neuropharmacology 38, 141.
      Beindle, W., et al. 1996. Mol. Pharmacol. 50, 415.
      Freissmuth, M., et al. 1996. Mol. Pharmacol. 49, 602.